A:-Phenytoin
B:-Cyclosporin
C:-Nifedipine
D:-Valproate
B:-Cyclosporin
C:-Nifedipine
D:-Valproate
Correct Answer:- Option-B
2:-Which of the benign tumors of gingiva has more incidence
A:-Fibroma
B:-Carcinoma
C:-Papilloma
D:-Giant cell tumor
B:-Carcinoma
C:-Papilloma
D:-Giant cell tumor
Correct Answer:- Option-A
3:-Stages in the progression of NUG was described by
A:-Pindborg
B:-Mc Carthy
C:-Plaut & Vincent
D:-Listgarten
B:-Mc Carthy
C:-Plaut & Vincent
D:-Listgarten
Correct Answer:- Option-A
4:-Zone 3 in electron microscopy of NUG correspond to
A:-Neutrophil rich zone
B:-Bacterial zone
C:-Necrotic zone
D:-Zone of spirochetal infiltration
B:-Bacterial zone
C:-Necrotic zone
D:-Zone of spirochetal infiltration
Correct Answer:- Option-C
5:-Most commonest mucocutaneous disease manifesting as desquamative gingivitis
A:-Pemphigus vulgaris
B:-Linear lgA disease
C:-Erosive lichen planus
D:-Lupus erythematosus
B:-Linear lgA disease
C:-Erosive lichen planus
D:-Lupus erythematosus
Correct Answer:- Option-C
6:-In periodontal pocket, zone of attachment of junctional epithelium to the tooth is reduced to
A:-500 μm
B:-More than 200 μm
C:-300 μm
D:-Less than 100 μm
B:-More than 200 μm
C:-300 μm
D:-Less than 100 μm
Correct Answer:- Option-D
7:-The distance from the attached plaque to the bone is never more than
A:-2.7 mm
B:-0.5 mm
C:-1.97 mm
D:-2 mm
B:-0.5 mm
C:-1.97 mm
D:-2 mm
Correct Answer:- Option-A
8:-Which inflammatory marker is increased in periodontitis which may act as intermediary step in pathway from periodontal infection to cardiovascular disease
A:-MMP
B:-PG
C:-CRP
D:-PAMP
B:-PG
C:-CRP
D:-PAMP
Correct Answer:- Option-C
9:-Presence or worsening of periodontal disease during pregnancy is associated with increased risk of preeclampsia about
A:-2-2.5 fold
B:-7 fold
C:-10 fold
D:-5 fold
B:-7 fold
C:-10 fold
D:-5 fold
Correct Answer:- Option-A
10:-Which drug can be given for reducing AGE production
A:-Penicillin
B:-Tetracycline
C:-Cephalosporin
D:-Macrolide
B:-Tetracycline
C:-Cephalosporin
D:-Macrolide
Correct Answer:- Option-C
0 Comments
Post a Comment